Breast Cancer
Hormone receptor-positive, HER2, and triple-negative subtypes
DefinitionClick to collapse
Breast cancer is a malignant neoplasm arising from the epithelial cells of the breast, encompassing a spectrum of diseases ranging from noninvasive ductal carcinoma in situ (DCIS) to invasive carcinomas with potential for metastasis. The NCCN Guidelines define breast cancer as the most common malignancy in females in the United States, with an estimated 313,510 new cases and 42,780 deaths in 2024 [1,2]. DCIS is characterized by proliferation of malignant epithelial cells confined to the mammary ducts without invasion through the basement membrane, staged as Tis,N0,M0 [DCIS-1]. Invasive breast cancer includes carcinoma of no special type (NST) and special histologic subtypes such as lobular, tubular, mucinous, and metaplastic carcinomas [BINV-4]. The primary tumor arises from the terminal duct-lobular unit, with embryological origin from ectodermal breast bud invaginating into mesenchyme. Anatomically, the breast extends from the clavicle to the inframammary fold and from the sternum to the midaxillary line, with lymphatic drainage primarily to axillary, internal mammary, and supraclavicular nodes [BINV-E]. Inflammatory breast cancer (IBC) is a distinct clinical entity defined by rapid onset of erythema, edema, and peau d'orange involving at least one-third of the breast, classified as T4d [IBC-1]. The AJCC TNM staging system categorizes disease based on tumor size, nodal involvement, and distant metastasis, with addition of biomarker status (ER, PR, HER2) and grade for prognostic staging [ST-1 to ST-11].
EpidemiologyClick to collapse
Breast cancer is the most common malignancy among women in the United States, with an estimated 313,510 new invasive cases and 42,780 deaths projected for 2024 [1,2]. The American Cancer Society reported that in 2022, over 50,000 cases of ductal carcinoma in situ (DCIS) were diagnosed [MS-3]. Incidence rates have been relatively stable, with a slight increase possibly due to screening and obesity trends. Breast cancer is the second leading cause of cancer death in women, after lung cancer [1]. Inflammatory breast cancer (IBC) accounts for 1-6% of breast cancer cases in the US [MS-93]. Approximately 5% of all breast cancer patients carry a germline BRCA1 or BRCA2 pathogenic variant, with higher prevalence among those with triple-negative disease [MS-83]. The median age at diagnosis is 62 years, and risk increases with age. Race/ethnicity disparities exist: Black women have a lower incidence than White women but a higher mortality rate (age-adjusted death rate approximately 40% higher) [1]. The lifetime risk of developing breast cancer in US women is about 13% (1 in 8). Five-year relative survival for localized breast cancer exceeds 99%, but for distant-stage disease it is approximately 31% [1]. DCIS incidence has increased since the introduction of screening mammography [MS-3]. Phyllodes tumors occur at a mean age of 40 years, younger than invasive ductal carcinoma [MS-90]. Pregnancy-associated breast cancer is infrequent, with 1.3 cases per 10,000 live births in a California registry study [MS-91]. Male breast cancer accounts for less than 1% of all breast cancers, and management recommendations are extrapolated from female breast cancer studies [BINV-J 1 of 2].
SubtypesClick to collapse
Ductal carcinoma in situ (DCIS)
Noninvasive proliferation of malignant epithelial cells within the mammary ducts without stromal invasion. Subclassified by nuclear grade (low, intermediate, high) and architectural pattern (e.g., comedo, cribriform, solid). Encapsulated papillary carcinoma without invasion is staged as pTis due to behavior similar to DCIS [DCIS-1].
Invasive carcinoma of no special type (NST)
Most common invasive breast cancer type, encompassing multiple patterns including medullary pattern, cancers with neuroendocrine expression, and other rare patterns [BINV-4]. Represents the default category when no special histologic pattern predominates.
Invasive lobular carcinoma
Characterized by discobesive cells that infiltrate stroma in a linear, single-file pattern. Often multifocal and bilateral. May be difficult to detect on mammography [BINV-1 footnote b, BINV-4].
Triple-negative breast cancer (TNBC)
Invasive breast cancer lacking expression of ER, PR, and HER2 (IHC 0 or 1+ or 2+/ISH negative). Associated with aggressive behavior and high risk of recurrence [BINV-10, BINV-Q 3 of 15].
HER2-positive breast cancer
Invasive breast cancer with overexpression/amplification of HER2 (ERBB2) defined as IHC 3+ or ISH ratio ≥2.0 with average HER2 copy number ≥4.0 signals/cell [BINV-A 2-3 of 4]. Includes both HR-positive and HR-negative subtypes.
Favorable histologic types
Includes pure tubular (≥90% tubular structures), pure mucinous (extracellular mucin >90%), pure cribriform, adenoid cystic carcinoma, secretory carcinoma, low-grade adenosquamous carcinoma, and other rare low-grade forms. Must be pure (>90% on surgical excision) and HER2-negative to be considered favorable [BINV-11].
Inflammatory breast cancer (IBC)
Clinical diagnosis requiring erythema, edema (peau d'orange) of at least one-third of the breast, with or without a palpable mass, and pathologic confirmation of invasive carcinoma. Dermal lymphatic invasion may be present but not required [IBC-1].
Paget disease of the breast
Rare manifestation characterized by neoplastic Paget cells in the epidermis of the nipple-areolar complex, presenting with eczema, ulceration, bleeding, or itching. Associated with underlying DCIS or invasive carcinoma in up to 80-90% of cases [PAGET-1, MS-88].
Phyllodes tumor
Rare fibroepithelial tumor composed of stromal and epithelial elements, classified as benign, borderline, or malignant [PHYLL-1]. Can be difficult to distinguish from fibroadenoma on core biopsy.
Molecular PathogenesisClick to collapse
Breast cancer arises through accumulation of genomic alterations that drive malignant transformation and progression. Key driver mutations include activating mutations in PIK3CA, which occur in approximately 40% of HR-positive, HER2-negative breast cancers and predict benefit from PI3Kα inhibitors (alpelisib, inavolisib) [MS-65; BINV-Q 6 of 15]. The PI3K/AKT/mTOR signaling pathway is frequently activated, with AKT1 and PTEN alterations also targetable by capivasertib [MS-65; BINV-Q 6 of 15]. ESR1 mutations, particularly in the ligand-binding domain, emerge under selective pressure of aromatase inhibitor therapy and are detected by ctDNA in approximately 30-40% of AI-resistant, HR-positive metastatic breast cancers; these are targetable by selective estrogen receptor degraders (elacestrant, imlunestrant, vepdegestrant) [MS-67-68; BINV-Q 6 of 15]. HER2 (ERBB2) amplification occurs in ~15-20% of breast cancers and defines a subtype driven by constitutive HER2 signaling, conferring sensitivity to trastuzumab, pertuzumab, T-DM1, and fam-trastuzumab deruxtecan [BINV-A 2-3 of 4]. Approximately 5% of breast cancers harbor germline BRCA1 or BRCA2 pathogenic variants, which cause defective homologous recombination repair and sensitivity to PARP inhibitors (olaparib, talazoparib) [MS-83; BINV-Q 7 of 15]. Additional germline mutations in PALB2, ATM, CHEK2, and TP53 contribute to hereditary breast cancer risk [MS-84; BINV-1 footnote f]. Somatic mutations in BRCA1/2 and other homologous recombination genes occur in a subset of TNBC [MS-85]. NTRK1/2/3 gene fusions are rare but targetable with larotrectinib, entrectinib, and repotrectinib [MS-84; BINV-Q 7 of 15]. RET gene fusions are targetable with selpercatinib [MS-85; BINV-Q 7 of 15]. Microsatellite instability-high (MSI-H)/mismatch repair deficiency (dMMR) and high tumor mutational burden (TMB-H ≥10 mut/Mb) are rare in breast cancer but confer sensitivity to PD-1 blockade (pembrolizumab) [MS-84-85; BINV-Q 7 of 15]. Chromosomal abnormalities include amplification of MYC, CCND1, and FGFR1, though these are not currently therapeutically targetable with FDA-approved drugs in breast cancer. The intrinsic molecular subtypes (luminal A, luminal B, HER2-enriched, basal-like) identified by gene expression profiling correlate with prognosis and treatment response, with basal-like (largely TNBC) showing high proliferation and genomic instability [MS-41; BINV-N 3 of 5].
Risk FactorsClick to collapse
Age
Incidence increases with age; median age at diagnosis 62 years. Young age (<50 years) is a significant predictor of increased likelihood of ipsilateral breast tumor recurrence after breast-conserving therapy [MS-13].
Germline BRCA1/2 pathogenic variants
Approximately 5% of all breast cancer patients carry germline BRCA1/2 mutations. Higher prevalence in triple-negative breast cancer (10-20%). Associated with high risk of breast and ovarian cancer [MS-83]. Genetic testing recommended for all patients with TNBC, those at risk per NCCN genetic criteria, and those being considered for adjuvant olaparib [BINV-1].
Other germline pathogenic variants (TP53, ATM, PALB2, CHEK2, CDH1, PTEN, STK11)
Rare mutations in TP53 (Li-Fraumeni syndrome) increase risk of phyllodes tumors and breast cancer [MS-90]. PALB2 mutations associated with homologous recombination deficiency and benefit from olaparib [MS-84]. ATM, CHEK2, CDH1, PTEN, and STK11 are established breast cancer susceptibility genes per NCCN genetic risk assessment guidelines [BINV-1 footnote f].
Family history of breast or ovarian cancer
Family history in a first-degree relative (mother, sister, daughter) increases risk. The NCCN Guidelines for Genetic/Familial High-Risk Assessment define criteria for genetic counseling based on family history patterns [BINV-1].
Obesity (BMI ≥30 kg/m²)
Obesity associated with increased risk of contralateral breast cancer in a nested case-control study of 369 patients with ER-positive tumors [MS-53]. Also associated with poorer outcomes for certain breast cancer subtypes.
Smoking
Smoking associated with increased risk of contralateral breast cancer in a nested case-control study [MS-53]. Smoking also increases complications in breast reconstruction (wound healing, necrosis, infection) [BINV-H 6 of 7].
Alcohol consumption
Alcohol consumption associated with increased risk of contralateral breast cancer [MS-53]. The NCCN Guidelines recommend limited alcohol intake for optimal breast cancer outcomes [BINV-17].
Dense breast tissue
Dense breasts are a risk factor for breast cancer and can mask tumors on mammography. MRI screening recommended for patients with dense breasts and history of breast cancer [BINV-B]. Annual MRI recommended for patients with prior breast cancer diagnosed at age ≤50 or with dense breasts [BINV-B].
Prior thoracic radiation therapy
History of prior RT to the affected area increases risk for subsequent breast cancer. Use of RT for treatment of Hodgkin lymphoma is a known risk factor. The NCCN Guidelines list prior RT as a relative contraindication to breast-conserving approaches requiring RT [BINV-G]. Knowledge of prior doses and volumes is important [BINV-G].
Menopausal hormone therapy
Menopausal hormone therapy is relatively contraindicated in survivors of hormonally mediated cancers; should be used with caution in those with increased genetic cancer risk [BINV-17]. The NCCN Guidelines for Survivorship provide further detail.
Clinical FeaturesClick to collapse
Typical Presentation
Breast cancer encompasses a spectrum of diseases ranging from non-invasive ductal carcinoma in situ (DCIS) to invasive carcinomas with distinct biological subtypes. DCIS is typically asymptomatic and detected on screening mammography as microcalcifications; symptoms such as a palpable mass, nipple discharge, or Paget disease may occur [DCIS-1]. Invasive breast cancer most commonly presents as a painless, firm breast mass or thickening, often discovered by the patient or on imaging. Other presentations include skin dimpling (peau d'orange), nipple retraction, erythema, or ulceration. Inflammatory breast cancer (IBC) is characterized by rapid onset (≤6 months) of erythema, edema, peau d'orange occupying ≥1/3 of the breast, with or without a palpable mass [IBC-1]. Paget disease presents with eczematous changes, ulceration, bleeding, or itching of the nipple-areolar complex [PAGET-1]. Phyllodes tumors present as a rapidly growing, painless, large (often >3 cm) mass, with imaging suggestive of fibroadenoma but with rapid growth [PHYLL-1]. Breast cancer in males typically presents as a painless retroareolar mass; due to rarity, diagnosis may be delayed. Pregnancy-associated breast cancer often presents with a mass, but diagnosis may be delayed due to physiologic breast changes [PREG-1].
Symptoms
breast mass or thickening
Most common symptom of invasive breast cancer; patients often detect a painless, firm lump.
nipple discharge
Can be serous, bloody, or watery; unilateral, spontaneous discharge is more concerning.
skin changes
Erythema, edema, peau d'orange, dimpling, or ulceration; characteristic of IBC and advanced tumors.
Paget disease of nipple
Eczema, ulceration, bleeding, or itching of nipple-areola; often associated with underlying carcinoma.
axillary mass
Enlarged lymph nodes may be first sign; can represent nodal metastasis from occult primary.
Signs
palpable breast mass
Firm, irregular, poorly mobile mass; may be tender in inflammatory cases.
skin edema/peau d'orange
Dermal lymphatic involvement causing skin thickening and pitting; hallmark of IBC.
nipple retraction or flattening
Due to tumor involvement of lactiferous ducts or fibrosis.
axillary lymphadenopathy
Palpable, firm, sometimes fixed nodes; may be the only sign in occult breast cancer.
inflammatory changes
Erythema, warmth, and edema; often mistaken for mastitis; requires urgent differentiation.
Red FlagsClick to collapse
Rapid onset of breast erythema, edema, and peau d'orange occupying ≥1/3 of the breast – suspicious for inflammatory breast cancer (IBC) and requires urgent biopsy and imaging [IBC-1].
Persistent nipple eczema, ulceration, bleeding, or itching – Paget disease; biopsy of nipple-areola complex is indicated [PAGET-1].
Rapid enlargement of a breast mass over weeks to months – may indicate phyllodes tumor or high-grade invasive cancer [PHYLL-1].
Fixed, matted axillary lymph nodes, supraclavicular lymphadenopathy, or skin ulceration – suggests advanced locoregional disease and requires systemic staging [BINV-1].
New neurological symptoms, back pain, or unexplained hypercalcemia – may indicate metastatic disease to CNS, spine, or bone; urgent imaging needed [BINV-18].
Weight loss, persistent cough, or abdominal pain – could indicate visceral metastases; perform CT imaging [BINV-18].
Bleeding from the nipple or skin breakdown over tumor – requires urgent surgical evaluation.
Inability to achieve negative margins after multiple attempts at breast-conserving surgery – may require mastectomy [BINV-F].
Pregnancy with breast cancer and need for RT or chemotherapy – requires coordination with obstetrics and consideration of timing to avoid harm to fetus [PREG-1].
Presence of germline BRCA1/2, PALB2, or TP53 mutation – increases risk for contralateral breast cancer and may influence surgical decisions [BINV-1].
InvestigationsClick to collapse
Diagnostic
Diagnostic bilateral mammogram
Primary imaging modality for detection and characterization of breast lesions; identifies microcalcifications, masses, and architectural distortion.
Breast ultrasound
Used to characterize lesions identified on mammogram, assess cystic/solid nature, and guide biopsy; also for axillary evaluation.
Core needle biopsy
Tissue diagnosis; prefer core over FNA for histologic subtype, grade, and biomarker assessment.
Full-thickness skin biopsy of nipple-areola
Diagnosis of Paget disease; identifies Paget cells in epidermis.
Breast MRI with IV contrast
Optional for further characterization of extent of disease, especially in dense breasts, mammographically occult tumors, or for evaluating axillary metastasis with occult primary.
Axillary ultrasound with FNA or core biopsy
Evaluates nodal status if suspicious for metastasis; guides surgical planning.
Staging
Chest diagnostic CT with contrast
Indicated for patients with signs/symptoms of metastatic disease or clinically high-risk (T3-4, N2-3); evaluates for lung/pleural metastases.
Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast
Assesses for liver, adrenal, and peritoneal metastases.
Bone scan or sodium fluoride PET/CT
Detects osteoblastic bone metastases; sodium fluoride PET/CT more sensitive but category 2B.
FDG-PET/CT
Useful in advanced disease (stage III) for detection of unsuspected nodal and distant metastases; can be performed with diagnostic CT.
Brain MRI with contrast
Evaluates for CNS metastases in patients with neurological symptoms.
Spine MRI with contrast
Assesses for spinal cord compression in patients with back pain or neurological symptoms.
Biomarkers
Estrogen receptor (ER) immunohistochemistry
Determines eligibility for endocrine therapy; 1–100% staining considered ER-positive; 1–10% is ER-low-positive.
Progesterone receptor (PR) immunohistochemistry
Aids in prognosis and serves as control for ER; positive if ≥1% nuclear staining.
HER2 (ERBB2) testing by IHC and/or ISH
Determines eligibility for HER2-targeted therapies; ASCO/CAP guidelines define positivity (IHC 3+ or ISH amplified).
Multigene panel testing (germline and somatic)
Identifies candidates for targeted therapies (e.g., PARP inhibitors for germline BRCA1/2, PIK3CA inhibitors, NTRK fusions).
PD-L1 testing (22C3 CPS)
Determines eligibility for pembrolizumab in advanced TNBC (first-line if CPS ≥10).
ESR1 mutation testing (ctDNA preferred)
Identifies resistance to aromatase inhibitors and eligibility for elacestrant, imlunestrant, or other SERDs.
PIK3CA/AKT1/PTEN mutation testing (NGS)
Determines eligibility for alpelisib, capivasertib, or inavolisib in HR+/HER2- metastatic breast cancer.
Germline BRCA1/2 testing
Identifies candidates for PARP inhibitors (olaparib, talazoparib) and influences surgical decisions.
Ki-67 immunohistochemistry
May aid in prognostication and treatment decisions, particularly for HR+/HER2- disease when considering adjuvant abemaciclib.
21-gene recurrence score (Oncotype DX) or other genomic assays
Provides prognostic and predictive information for chemotherapy benefit in HR+/HER2- early breast cancer.
StagingClick to collapse
AJCC 8th edition, TNM staging for breast cancer (Anatomic Stage Groups and Prognostic Stage Groups) [ST-1 to ST-11]
T Categories
| Stage | Description |
|---|---|
| TX | Primary tumor cannot be assessed. |
| T0 | No evidence of primary tumor. |
| Tis (DCIS) | Ductal carcinoma in situ. |
| Tis (Paget) | Paget disease of the nipple NOT associated with invasive carcinoma and/or DCIS in the underlying parenchyma. |
| T1mi | Tumor ≤1 mm in greatest dimension (microinvasive). |
| T1a | Tumor >1 mm but ≤5 mm (round any measurement >1.0–1.9 mm to 2 mm). |
| T1b | Tumor >5 mm but ≤10 mm. |
| T1c | Tumor >10 mm but ≤20 mm. |
| T2 | Tumor >20 mm but ≤50 mm. |
| T3 | Tumor >50 mm. |
| T4a | Extension to chest wall (not including pectoralis muscle alone). |
| T4b | Ulceration and/or ipsilateral macroscopic satellite nodules and/or edema (peau d'orange) of skin not meeting inflammatory carcinoma criteria. |
| T4c | Both T4a and T4b. |
| T4d | Inflammatory carcinoma (clinical diagnosis of erythema and edema involving ≥1/3 of the breast). |
N Categories
| Stage | Description |
|---|---|
| cNX | Regional lymph nodes cannot be assessed (e.g., previously removed). |
| cN0 | No regional lymph node metastases by imaging or clinical examination. |
| cN1 | Metastases to movable ipsilateral level I, II axillary lymph node(s). (Also includes cN1mi: micrometastases >0.2 mm but ≤2.0 mm.) |
| cN2a | Metastases in ipsilateral level I, II axillary nodes fixed or matted to each other or to other structures. |
| cN2b | Metastases only in ipsilateral internal mammary nodes in the absence of axillary node metastases. |
| cN3a | Metastases in ipsilateral infraclavicular (level III axillary) node(s). |
| cN3b | Metastases in ipsilateral internal mammary node(s) and axillary node(s). |
| cN3c | Metastases in ipsilateral supraclavicular node(s). |
| pNX | Regional nodes cannot be assessed (e.g., not removed or previously removed). |
| pN0 | No regional lymph node metastasis identified or ITCs only. |
| pN0(i+) | ITCs only (malignant cell clusters ≤0.2 mm). |
| pN0(mol+) | Positive molecular findings by RT-PCR; no ITCs detected. |
| pN1mi | Micrometastases (>0.2 mm but ≤2.0 mm). |
| pN1a | Metastases in 1–3 axillary lymph nodes, at least one >2.0 mm. |
| pN1b | Metastases in ipsilateral internal mammary sentinel nodes (excluding ITCs). |
| pN1c | Combined pN1a and pN1b. |
| pN2a | Metastases in 4–9 axillary lymph nodes (at least one >2.0 mm). |
| pN2b | Metastases in clinically detected internal mammary nodes with pathologically negative axillary nodes. |
| pN3a | Metastases in ≥10 axillary nodes, or metastases to infraclavicular (level III) nodes. |
| pN3b | pN1a or pN2a in the presence of cN2b (positive internal mammary nodes by imaging); or pN2a in the presence of pN1b. |
| pN3c | Metastases in ipsilateral supraclavicular nodes. |
M Categories
| Stage | Description |
|---|---|
| M0 | No clinical or radiographic evidence of distant metastases. |
| cM0(i+) | No clinical or radiographic evidence of distant metastases but tumor cells or deposits ≤0.2 mm detected by microscopy or molecular techniques in circulating blood, bone marrow, or nonregional nodal tissue without symptoms or signs of metastases. |
| cM1 | Distant metastases detected by clinical and radiographic means. |
| pM1 | Any histologically proven metastases in distant organs; or nonregional nodes with metastases >0.2 mm. |
Stage Groupings
| Group | Criteria | Clinical Meaning | Five Yr Survival | Treatment Intent |
|---|---|---|---|---|
| Stage 0 | Tis N0 M0 | Non-invasive cancer (DCIS or Paget without invasion). | None | Curative – local therapy (surgery ± RT, endocrine therapy if ER+ DCIS) |
| Stage IA | T1* N0 M0 (*T1 includes T1mi) | Small invasive tumor (≤2 cm) with no nodal involvement. | None | Curative – surgery ± RT, endocrine therapy if HR+, consider chemotherapy based on risk |
| Stage IB | T0 N1mi M0 or T1 N1mi M0 | Tumor with nodal micrometastases only. | None | Curative – similar to stage IA with consideration of axillary management |
| Stage IIA | T0 N1 M0; T1 N1 M0; T2 N0 M0 | Node-positive (1–3 nodes) with small tumor or larger node-negative tumor. | None | Curative – surgery ± RT, systemic therapy based on biomarkers |
| Stage IIB | T2 N1 M0; T3 N0 M0 | Larger tumor or node-positive. | None | Curative – surgery, systemic therapy, RT as indicated |
| Stage IIIA | T0 N2 M0; T1 N2 M0; T2 N2 M0; T3 N1 M0; T3 N2 M0 | Locally advanced – extensive nodal involvement (4–9 nodes) or larger primary with nodal spread. | None | Curative with multimodal therapy (chemotherapy, surgery, RT) |
| Stage IIIB | T4 N0–N2 M0 | Chest wall/skin involvement (including inflammatory breast cancer) with or without regional nodal disease. | None | Curative with multimodal therapy (systemic therapy, surgery, RT); IBC requires neoadjuvant chemotherapy |
| Stage IIIC | Any T N3 M0 | Regional nodal involvement including supraclavicular or internal mammary nodes. | None | Curative with aggressive multimodal therapy |
| Stage IV | Any T Any N M1 | Distant metastases present. | None | Palliative – systemic therapy ± local therapy for symptom control; consider locoregional treatment for de novo oligometastatic disease with favorable features [BINV-18] |
Staging Pearls
- The AJCC 8th edition includes both Anatomic Stage Groups and Prognostic Stage Groups (Clinical and Pathological), which incorporate grade, HER2, ER, and PR status [ST-6–ST-11].
- For patients treated with preoperative systemic therapy, stage designation uses 'yc' or 'yp' prefixes; no anatomic stage group is assigned if pCR is achieved (e.g., ypT0ypN0cM0) [ST-3].
- Inflammatory breast cancer (IBC) is staged as T4d regardless of tumor size; requires clinical diagnosis of erythema and edema occupying ≥1/3 of breast [IBC-1, ST-1].
- Lobular carcinoma in situ (LCIS) is considered a benign entity and removed from AJCC staging (8th ed.) [ST-1].
- Micrometastases (N1mi) are staged as IB if T0 or T1; for T2–4, they are included in the N1 category [ST-3].
- Clinical staging should be used for patients receiving preoperative systemic therapy; final staging is based on pathologic findings after surgery.
- The Prognostic Stage Groups are based on populations treated with appropriate endocrine and/or systemic chemotherapy (including anti-HER2 therapy) [ST-8].
- Oncotype DX recurrence score <11 in T1–2N0 HER2-negative ER-positive cancer assigns Pathological Prognostic Stage IA regardless of grade [ST-11].
Management PrinciplesClick to collapse
Breast cancer management requires a multimodal, multidisciplinary approach integrating surgery, radiation therapy, systemic therapy (chemotherapy, endocrine therapy, targeted therapy, immunotherapy), and supportive care. Treatment selection is driven by tumor biology (ER/PR, HER2 status, Ki-67, genomic assays), anatomic stage (TNM), patient menopausal status, genetic predisposition (e.g., BRCA1/2), and performance status. The NCCN Guidelines stress individualized shared decision-making, clinical trial participation, and coordination among surgical, radiation, medical oncologists, pathologists, and reconstructive surgeons [MS-1, MS-2]. For early-stage disease, locoregional control (BCS + RT or mastectomy ± PMRT) and systemic therapy (adjuvant or preoperative) aim to reduce recurrence risk. For metastatic disease, goals are palliation, prolongation of survival, and quality of life maintenance [BINV-21, BINV-28].
Curative (early-stage non-metastatic)
cT1–3, cN0 or N+, M0 invasive breast cancer and DCIS
Surgery (BCS or mastectomy) ± RT ± adjuvant systemic therapy based on receptor status, genomic risk, and nodal involvement. Preoperative systemic therapy preferred for HER2+ or TNBC ≥cT2 or ≥cN1, or for large primary relative to breast size [BINV-L 1].
Preoperative/Neoadjuvant
Inoperable (IBC, cT4, cN2–3) or select operable (HER2+, TNBC, large tumor)
Systemic therapy (chemotherapy ± HER2-targeted therapy ± immunotherapy) followed by surgery and adjuvant therapy as indicated. Response guides subsequent locoregional and systemic decisions [BINV-L, BINV-14, BINV-15].
Palliative (metastatic/recurrent)
Stage IV (M1) or unresectable local/regional recurrence
Systemic therapy (endocrine ± targeted therapy, chemotherapy, ADCs, immunotherapy) with supportive care. Bone-modifying agents for bone metastases. Local therapy reserved for palliation or selected oligometastatic cases [BINV-21, BINV-28].
Multidisciplinary team should include surgical oncologist, radiation oncologist, medical oncologist, pathologist, radiologist, reconstructive surgeon, genetic counselor, fertility specialist, and supportive care providers. Coordination is essential for sequencing of surgery, RT, and systemic therapy. Regular tumor board discussions are recommended [BINV-1, BINV-18, MS-2].
Performance status is assessed using ECOG or Karnofsky scales. For adjuvant therapy, all patients with adequate PS are candidates. In metastatic setting, PS guides chemotherapy vs. endocrine-based therapy; patients with PS >2 may be better suited for endocrine therapy or supportive care alone. The PANEL recommends assessing PS at each reassessment to determine ongoing treatment value [BINV-M 1, BINV-Q 1, BINV-23, BINV-27].
Management PathwaysClick to collapse
Branching: Tumor ER status, Patient age and risk factors, Surgical margin status
Branching: Nodal status (pN0 vs. pN1–3 vs. pN2–3), 21-gene recurrence score (RS) when applicable, Menopausal status, Comorbidities and patient preference
Branching: Tumor size and grade, 21-gene recurrence score (RS), Ovarian function and desire for fertility, Age
Branching: Nodal category (pN1mi, pN1, pN2–3), Gene expression assay RS, Germline BRCA1/2 status, Ovarian function
Branching: Nodal status (pN0, pN1mi, pN+), Tumor size (pT1a, pT1b, pT1c–T3), Adjuvant vs. preoperative therapy, Risk of recurrence
Branching: Tumor size and nodal status, Adjuvant vs. preoperative therapy
Branching: Tumor size and nodal status, Stage (I vs. II–III), Germline BRCA1/2 PV status, PD-L1 CPS (for metastatic), Residual disease after preoperative therapy
Branching: Tumor size, Nodal status, ER/PR status
Branching: HR status, HER2 status, Response to preoperative systemic therapy
Branching: Presence of associated breast cancer (DCIS or invasive) on imaging/biopsy, ER/PR/HER2 status of associated cancer
Branching: Core biopsy result (benign, indeterminate, suspicious for borderline/malignant), Surgical margin status
Branching: Trimester at diagnosis, Patient decision regarding pregnancy continuation, Stage and receptor status
Branching: Presence of visceral crisis, Prior endocrine therapy and disease-free interval, Germline BRCA1/2 PV status, Biomarkers: PIK3CA, AKT1, PTEN, ESR1, HER2 low/ultralow status
Branching: Prior HER2-directed therapy, HR status, CNS involvement, Prior pertuzumab, T-DM1, tucatinib
Branching: PD-L1 CPS score, Germline BRCA1/2 PV status, HER2 low/ultralow status, Prior treatment lines
Branching: Operability at presentation, Receptor subtype (HR, HER2), Clinical and pathologic response, Residual disease status
Pretreatment EvaluationClick to collapse
Clinical and Imaging
Pathology and Biomarkers
Patient Assessment and Support
SurgeryClick to collapse
Surgery is a cornerstone of locoregional treatment for breast cancer. For early-stage invasive cancer and DCIS, options are breast-conserving surgery (BCS) or mastectomy, both with equivalent survival outcomes when combined with appropriate adjuvant therapy. Axillary staging (sentinel lymph node biopsy or axillary lymph node dissection) guides systemic and radiation decisions. Preoperative systemic therapy can convert inoperable tumors to operable and increase BCS rates. For metastatic disease, role of primary tumor surgery is limited to palliation, with no proven survival benefit in prospective trials [MS-13–MS-18, BINV-2, BINV-3, BINV-14, BINV-15].
The choice between BCS and mastectomy should be based on patient preference, tumor characteristics, ability to achieve negative margins, contraindications to RT, and genetic predisposition. BCS + RT offers equivalent survival to mastectomy (category 1) [BINV-2, BINV-3].
Negative margins are defined as 'no ink on tumor' for invasive cancer and DCIS component; for pure DCIS, ≥2 mm margin recommended. Re-excision should be attempted to achieve negative margins before converting to mastectomy [BINV-F].
Axillary staging: SLNB is preferred for clinically node-negative patients. ALND (level I/II) is indicated for biopsy-proven nodal metastases (without preoperative therapy) or residual disease after preoperative therapy. Omission of axillary staging may be considered in selected low-risk patients (e.g., >50 yrs, HR+/HER2-, grade 1–2, cT1N0) based on SOUND/INSEMA trials [BINV-D, BINV-E, footnote b].
For patients with clinically positive nodes converting to cN0 after preoperative systemic therapy, SLNB with targeted axillary dissection (TAD) of clipped node reduces false-negative rate. ALND still standard if SLN positive after preoperative therapy [BINV-D, BINV-14].
Oncoplastic techniques and reconstruction should be offered to patients undergoing mastectomy or BCS to optimize cosmetic outcomes. Skin-sparing and nipple-sparing mastectomy are options with careful patient selection [BINV-H].
For inflammatory breast cancer, mastectomy with level I/II ALND is recommended; skin-sparing and nipple-sparing are contraindicated. Delayed reconstruction is standard [IBC-2].
Procedures
Sentinel Lymph Node Biopsy (SLNB)
Clinically node-negative invasive breast cancer (cN0). For DCIS, consider only if mastectomy, concern for invasion, or oncoplastic BCS. For cN+ converting to cN0 after preoperative therapy, use with TAD [BINV-D, BINV-E].
Axillary Lymph Node Dissection (ALND) – Level I/II
Biopsy-proven axillary metastases (no preoperative therapy), residual disease after preoperative therapy, failed SLNB, or SLN-positive not meeting ACOSOG Z0011 criteria (e.g., mastectomy, >2 SLN+, T3, preoperative chemo). Also for clinically positive nodes [BINV-D, BINV-E].
Breast-Conserving Surgery (BCS) / Lumpectomy / Partial Mastectomy
All patients suitable for breast conservation: no contraindications (e.g., diffuse disease, multicentric with high-risk features, inability to receive RT, inflammatory cancer). For multicentric disease with specific criteria (age ≤40, TNBC, BRCA carrier, etc.), mastectomy may be mandated [BINV-2, BINV-G].
Total Mastectomy
Patient choice, inability to obtain negative margins with BCS, contraindications to RT, inflammatory breast cancer, extensive disease, multicentric disease with high-risk features, homozygous ATM mutation (category 2B contraindication to BCS) [BINV-3, BINV-G].
Targeted Axillary Dissection (TAD)
Clinically node-positive patients who convert to cN0 after preoperative systemic therapy and desire SLNB alone instead of ALND [BINV-D, footnote k].
Radiation TherapyClick to collapse
Radiation therapy is an integral component of breast cancer management, used for local control after BCS (whole breast RT or APBI), after mastectomy (PMRT) in high-risk patients, and for regional nodal irradiation (RNI) in node-positive disease. RT also has a role in palliation of metastatic sites. Hypofractionation is the preferred schedule for whole breast and chest wall RT. RT sequencing with systemic therapy generally follows chemotherapy; concurrent use with CMF is acceptable but not with capecitabine or olaparib [BINV-I, MS-18–MS-25].
Principles
- Individualize RT planning using 3D CT-based planning with target volume delineation and organs at risk (heart, lung) constraints. Use DIBH, prone positioning, cardiac blocks to reduce cardiac dose [BINV-I 1].
- Hypofractionated WBRT (40–42.5 Gy/15–16 fractions) is preferred; conventional fractionation (45–50.4 Gy/25–28 fractions) may be used in selected cases. Boost to tumor bed (10–16 Gy/4–8 fx) for higher-risk patients [BINV-I 1].
- Ultra-hypofractionation (28.5 Gy/5 weekly fractions or 26 Gy/5 daily fractions) may be considered for selected low-risk patients; optimal boost technique not established [BINV-I 1].
- PMRT indicated for: 1–3 positive nodes (strongly consider) and ≥4 positive nodes (category 1). Consider for node-negative with high-risk features (T3, central/medial, grade 3, ER-negative, young age, LVI). For patients with positive margins after neoadjuvant therapy, if re-excision not feasible, strongly consider PMRT [BINV-I 2, BINV-3].
- RNI includes supraclavicular, infraclavicular, internal mammary, and axillary nodes at risk. Internal mammary coverage individually based on tumor location and nodal involvement. Dose: 46–50 Gy conventional or 39–42.56 Gy hypofractionated [BINV-I 2].
- For patients receiving preoperative systemic therapy, RT decisions based on maximal stage (initial clinical stage + pathologic response). For cN1 ypN0, RNI not routinely indicated (NSABP B-51 data); for cN2–3 ypN0 or any ypN+, comprehensive RNI recommended [BINV-14, BINV-I 2].
Dose Frameworks
| Name | Total Dose | Dose Per Fraction | Fractions | Schedule | Indication |
|---|---|---|---|---|---|
| Conventional WBRT | 45–50.4 Gy | 1.8–2 Gy | 25–28 | Once daily, 5 days/week | Selected cases when hypofractionation not suitable (e.g., large breast, reconstruction) [BINV-I 1] |
| Moderate Hypofractionation (WBRT or Chest Wall) | 40–42.5 Gy | 2.66–2.67 Gy | 15–16 | Once daily for 3 weeks | Preferred for whole breast RT; also used for chest wall and RNI [BINV-I 1, BINV-I 2] |
| Ultra-Hypofractionation (WBRT) | 26 Gy or 28.5 Gy | 5.2 Gy (26 Gy/5) or 5.7 Gy (28.5 Gy/5) | 5 | 26 Gy daily; 28.5 Gy once weekly for 5 weeks | Select patients >50 yrs with early-stage, node-negative disease; boost not established [BINV-I 1] |
| Boost to Tumor Bed | 10–16 Gy | 2–2.5 Gy | 4–8 | Sequential after WBRT or as simultaneous integrated boost (48 Gy/15 fx with WBRT 40 Gy/15 fx) | Higher risk (age <50, high grade, positive margins, DCIS with boost benefit) [BINV-I 1] |
| APBI (External Beam) | 30 Gy | 6 Gy | 5 | Every other day; IMRT/VMAT mandated | Preferred APBI regimen for patients meeting ASTRO 2024 criteria: ≥40 yrs, ER+, ≤2 cm, grade 1–2, negative margins, node-negative [BINV-I 3] |
| APBI (Brachytherapy) | 34 Gy/10 fx BID, 32 Gy/8 fx BID, or 30.1 Gy/7 fx BID | Variable | 7–10 | Twice daily | Same patient selection as external beam APBI [BINV-I 3] |
Approaches
| Name | Dose Fractionation | Concurrent Chemotherapy | Indication | Key Trial | Toxicities |
|---|---|---|---|---|---|
| Whole Breast RT (WBRT) after BCS | 40–42.5 Gy/15–16 fx preferred; 45–50.4 Gy/25–28 fx optional; boost 10–16 Gy/4–8 fx | CMF can be given concurrently; capecitabine after RT; olaparib after RT; endocrine therapy can be concurrent or sequential [BINV-I 2] | After BCS for invasive cancer and DCIS; category 1 for node-positive, category 2A for node-negative. Omission may be considered for low-risk patients ≥70 yrs with ER+ T1N0 (category 1) or ≥65 yrs with T ≤3 cm and endocrine therapy [BINV-2] | EBCTCG meta-analysis: WBRT reduces 10-yr recurrence and 15-yr breast cancer mortality (RR 0.52, 0.82 respectively) [MS-21]. | Skin reaction, fatigue, breast edema, fibrosis, telangiectasia; cardiac (left-sided); lung (pneumonitis) – reduced with DIBH and hypofractionation. |
| Post-Mastectomy RT (PMRT) | 45–50.4 Gy/25–28 fx or 40–42.5 Gy/15–16 fx; scar boost 10 Gy/4–5 fx if high risk; bolus for skin involvement | None (capecitabine, olaparib after RT); endocrine and HER2 therapy may be concurrent [BINV-I 2] | All node-positive patients (category 1 for ≥4 nodes; strongly consider for 1–3 nodes). Consider for node-negative with T3, positive margins, or high-risk features. For IBC: mandatory [BINV-3, IBC-2] | EBCTCG meta-analysis: PMRT reduces recurrence and breast cancer mortality in node-positive patients [MS-23]. | Chest wall skin changes, fibrosis; cardiac, lung; lymphedema; impaired reconstruction cosmesis (higher with implant). |
| Regional Nodal Irradiation (RNI) | 46–50 Gy/25–28 fx or 39–42.56 Gy/15–16 fx; boost to grossly involved nodes | Same as above | For node-positive disease: ≥4 positive nodes (category 1); 1–3 nodes: strongly consider, especially if central/medial tumors, T3, or other risk factors. Also for cN2–3 ypN0 or any ypN+ after preoperative therapy [BINV-2, BINV-14, BINV-I 2] | MA.20: improved DFS (82% vs 77%) and reduced distant recurrence with RNI. EORTC 22922: improved breast cancer mortality at 15 years [MS-20, MS-21]. | Increased cardiac dose (especially internal mammary); lung; lymphedema; potential brachial plexopathy (rare). |
| Accelerated Partial Breast Irradiation (APBI) | 30 Gy/5 fx QOD (preferred) or 40 Gy/15 fx; brachytherapy options | Can be administered prior to chemotherapy if needed [BINV-2, footnote v] | For patients without germline BRCA1/2 PV meeting ASTRO 2024 criteria: ≥40 yrs, ER+ invasive DC ≤2 cm, grade 1–2, negative margins, no LVSI, node-negative. Also for DCIS ≤2 cm, low- to intermediate-grade, negative margins [BINV-I 3] | Florence trial (APBI vs WBRT): comparable local control; better cosmesis and less toxicity with APBI. NSABP B-39: 10-yr IBTR 4.6% vs 3.9% (not equivalent but small absolute difference) [MS-21]. | Lower acute toxicity; fair/poor cosmesis in some studies (especially 3D conformal); fat necrosis, breast pain. |
Systemic TherapyClick to collapse
Systemic therapy for breast cancer includes endocrine therapy, chemotherapy, HER2-targeted therapy, immunotherapy (checkpoint inhibitors), antibody-drug conjugates, PARP inhibitors, and other targeted therapies. Treatment decisions are based on tumor subtype (HR/HER2), stage, genomic profiles, menopausal status, germline mutations, and patient fitness. For early-stage disease, adjuvant systemic therapy reduces recurrence and mortality. Preoperative systemic therapy is preferred for high-risk subtypes (TNBC, HER2+) and for downstaging. For metastatic disease, sequential therapy is used with goals of prolonging survival and maintaining quality of life. The NCCN Guidelines provide comprehensive regimens with dosing schedules and toxicity management [BINV-M, BINV-Q, MS-30–MS-86].
Key Regimens
Treatment Response AssessmentClick to collapse
Title
Assessment of Treatment Response and Monitoring
Timing
For preoperative systemic therapy, response should be assessed routinely by clinical exam and imaging (mammogram, ultrasound, MRI) during therapy. MRI is more accurate than mammography for assessing tumor response. Imaging methods should be determined by the multidisciplinary team. Standard regimen should be completed before surgery; if progression, consider alternative systemic therapy or proceed to surgery if resectable [BINV-L 2, BINV-15]. For metastatic disease, monitoring intervals vary by treatment type: chemotherapy every 2–4 cycles, endocrine therapy every 2–6 months. CT chest/abdomen/pelvis and bone scan every 2–6 cycles or 2–6 months. PET/CT as clinically indicated. Tumor markers (CEA, CA 15-3, CA 27.29) as clinically indicated; rising markers alone rarely used to declare progression [BINV-R 3].
Response Logic
-
For preoperative therapy, pathologic complete response (pCR) defined as ypT0 ypN0 (or ypT0/is ypN0) is associated with favorable prognosis, especially in TNBC and HER2+. Residual cancer burden (RCB) provides prognostic information (category 2B recommendation) [BINV-L 2].
-
For metastatic disease, use RECIST 1.1 or WHO criteria to define response, stability, or progression. Same imaging modality should be used over time. Functional imaging (bone scan, PET) may show flare in responding disease [BINV-R 2].
-
Progression is defined by unequivocal evidence: worsening symptoms, declining performance status, new or enlarging lesions on imaging, increasing tumor markers (with caution). Rising tumor markers alone rarely declare progression; clinical correlation needed [BINV-R 1].
-
For patients on immunotherapy, pseudoprogression may occur; confirmatory imaging before declaring progression may be needed. Manage immune-related adverse events per NCCN guidelines for immune checkpoint inhibitor toxicities [BINV-M 1, BINV-Q 1].
Imaging Recommendations
-
Baseline prior to new therapy: CT chest/abdomen/pelvis with contrast; bone scan or sodium fluoride PET/CT; FDG-PET/CT as indicated. Brain MRI with contrast if CNS symptoms [BINV-18, BINV-R 3].
-
During chemotherapy: symptom assessment, physical exam, PS, weight, LFTs, CBC prior to each cycle. CT chest/abdomen/pelvis every 2–4 cycles. Bone scan every 4–6 cycles. PET/CT as clinically indicated [BINV-R 3].
-
During endocrine therapy: same assessment every 1–3 months. CT every 2–6 months; bone scan every 2–6 months. Frequency can be reduced for patients with long-term stable disease [BINV-R 3].
-
Post-treatment surveillance for early-stage: mammography every 12 months (starting 6–12 months after RT for BCS). No routine imaging for reconstructed breast after mastectomy. No routine laboratory or imaging for metastases in asymptomatic patients [BINV-17].
Biopsy Or Salvage Logic
-
For metastatic disease, biopsy of first recurrence is recommended to confirm ER/PR/HER2 status. Re-biopsy at progression should be considered if management may change. Discordance between primary and metastatic sites is well-documented; ER/PgR and HER2 status can change with treatment [BINV-18, BINV-A].
-
ctDNA (liquid biopsy) for ESR1 mutations at progression after prior endocrine therapy (preferred over tissue). If ESR1 negative and tumor fraction low, consider reflex tissue-based NGS. Tissue biopsy preferred for PTEN homozygous copy loss or TMB-H [BINV-Q 6, footnote w].
-
For isolated locoregional recurrence, biopsy to confirm and repeat biomarker testing. Surgical resection with negative margins if feasible, followed by RT (if not previously irradiated) or re-irradiation (if feasible). Consider systemic therapy after local treatment (CALOR trial: chemotherapy benefit mainly for ER-negative) [BINV-19, BINV-20, MS-56].
-
For oligometastatic de novo disease, aggressive multimodality approach (locoregional therapy of primary + ablative treatment of metastases + 'adjuvant-like' systemic therapy) may be considered in favorable cases (HER2+, ER+, limited sites, bone-only, induced NED). Prospective trials have not shown survival improvement but may reduce local progression [BINV-18].
SurveillanceClick to collapse
Clinical Follow Up Schedule
| Phase | Frequency |
|---|---|
| First 5 years after curative treatment | History and physical exam every 6–12 months (DCIS: 6–12 months; invasive: 1–4 times per year as clinically appropriate), then annually after 5 years. |
| Mammography | Every 12 months, starting 6–12 months after completion of RT (for BCS) or after BCS if no RT. |
| Genetic screening (if indicated) | Periodic screening for changes in family history and genetic testing indications. |
| BMD monitoring | Baseline and periodically (e.g., every 1–2 years depending on risk) for patients on AI or with ovarian failure. |
Imaging Strategy
| Modality | Schedule |
|---|---|
| Mammography | Annual mammogram; first post-treatment mammogram 6–12 months after RT, then annually. Suspicious findings warrant immediate workup. Routine imaging of reconstructed breast after mastectomy not indicated [BINV-17]. |
| Breast MRI | Not routinely indicated for follow-up; consider for those with high lifetime risk (>20% based on family history) or personal history of breast cancer diagnosed at ≤50 years or dense breasts per ACR recommendations [BINV-B]. |
| Staging imaging (CT, bone scan, PET/CT) for metastases | Not recommended for asymptomatic patients. Only if signs/symptoms of recurrence [BINV-17]. |
Laboratory Monitoring
| Test | Schedule |
|---|---|
| CBC, LFTs, alkaline phosphatase | Not routinely indicated for metastatic surveillance in asymptomatic patients. If patient on tamoxifen, no routine labs; on AI, consider periodic LFTs and renal function as indicated. |
| Tumor markers (CEA, CA 15-3, CA 27.29) | Not recommended for routine surveillance. An isolated increase should rarely be used to declare progression [BINV-R]. |
Supportive Follow Up
- Assess and encourage adherence to adjuvant endocrine therapy [BINV-17].
- Educate about active lifestyle, healthy diet, limited alcohol, ideal body weight (BMI 20–25) [BINV-17].
- Monitor for hormonal therapy side effects: hot flashes, mood changes, arthralgias; consider venlafaxine for hot flashes [332-335].
- Provide psychosocial support: screen for distress, fear of recurrence, depression; refer to mental health professionals as needed [BINV-17].
- Coordinate care between PCP and specialists; provide survivorship treatment plan including summary of possible long-term toxicities [BINV-17].
- For premenopausal patients: fertility counseling, non-hormonal birth control, and sexual health considerations [BINV-C].
ComplicationsClick to collapse
Disease-Related
| Complication | Management |
|---|---|
| Pain from bone metastases | Bisphosphonates (zoledronic acid, pamidronate) or denosumab (category 1) plus calcium/vitamin D; palliative RT; surgery for impending fracture or cord compression [BINV-21]. |
| Malignant wounds, skin ulceration, bleeding, fungation | Palliative surgery, RT, wound care; consider systemic therapy to best response then surgical resection if feasible [BINV-19, BINV-20]. |
| Brain metastases (especially in HER2-positive and TNBC) | See NCCN Guidelines for CNS Cancers; consider SRS, WBRT, surgery. Tucatinib + capecitabine + trastuzumab preferred for CNS progression in HER2+ disease [BINV-Q 4]. |
| Lymphedema | Educate, monitor, refer for lymphedema management (see NCCN Survivorship: Lymphedema). Baseline arm measurements recommended [BINV-E, BINV-17]. |
| Spinal cord compression | Urgent MRI, spine MRI with contrast if back pain/symptoms; RT, surgery, corticosteroids [BINV-18]. |
Supportive CareClick to collapse
Supportive care should be integrated throughout the continuum of breast cancer care. This includes management of symptoms from the disease (e.g., pain, dyspnea, malignant wounds) and from treatment (e.g., neutropenia, nausea, peripheral neuropathy, cardiotoxicity, fatigue, depression, and lymphedema). Early involvement of palliative care is recommended for advanced disease. Regular screening for distress, anxiety, depression, and fear of recurrence is essential. See NCCN Guidelines for Distress Management, Survivorship, Palliative Care, and Supportive Care [BINV-28].
Encourage healthy diet, active lifestyle, limited alcohol intake, and maintaining ideal body weight (BMI 20–25) to optimize outcomes [BINV-17]. For patients with metastatic disease, address anorexia, cachexia, and malnutrition (see NCCN Palliative Care). Supplemental calcium and vitamin D needed with bisphosphonate/denosumab therapy [BINV-21].
Refer to NCCN Guidelines for Antiemesis. For chemotherapy, use appropriate antiemetic regimens based on emetogenicity (e.g., NK1 inhibitors, 5-HT3 antagonists, steroids). Avoid NK1 inhibitors during pregnancy [PREG-2]. Ondansetron and metoclopramide are considered safe during pregnancy [PREG-2].
Primary prophylaxis with G-CSF is recommended for dose-dense chemotherapy regimens (e.g., dose-dense AC → paclitaxel) and for regimens with high febrile neutropenia risk. See NCCN Guidelines for Hematopoietic Growth Factors [BINV-M 5, BINV-M 6].
Consider VTE risk, especially when combining abemaciclib with tamoxifen [BINV-K 3]. For hospitalized patients with cancer, use prophylactic anticoagulation per guidelines. There is no specific VTE prophylaxis recommendation for ambulatory breast cancer patients in the source.
Follow NCCN Guidelines for Adult Cancer Pain. For bone metastases, use bisphosphonates/denosumab, palliative RT, and analgesics. For neuropathic pain from TIPN, consider dose reduction or alternative agents (e.g., docetaxel instead of paclitaxel for high-risk patients) [BINV-M 1].
Screen for distress using NCCN Distress Thermometer at initial diagnosis and periodically. Assess for anxiety, depression, fear of progression, PTSD, and social determinants of health. Provide resources through financial navigators, social workers, and support groups. For young patients, address fertility and sexual health concerns [BINV-1, BINV-17, BINV-28].
Dental examination with preventive dentistry is required before initiating bisphosphonate or denosumab therapy to reduce risk of osteonecrosis of the jaw (ONJ). Avoid invasive dental procedures during therapy if possible [BINV-17, BINV-21].
PrognosisClick to collapse
Breast cancer is the most common malignancy in females in the US, with an estimated 313,510 new cases and 42,780 deaths in 2024 [1,2]. Prognosis varies widely by stage, subtype, and treatment response. For ductal carcinoma in situ (DCIS), 15-year breast cancer mortality is approximately 1.7% with breast-conserving therapy (BCT) versus 2.3% with breast-conserving surgery (BCS) alone (HR 0.77; 95% CI 0.67–0.88; P<.001) [29]. For early-stage invasive breast cancer, the EBCTCG meta-analysis demonstrated that adjuvant radiotherapy reduces 10-year recurrence risk from 35% to 19% (RR 0.52; 95% CI 0.48–0.56) and 15-year breast cancer death from 25% to 21% (RR 0.82; 95% CI 0.75–0.90) [117]. Pathologic complete response (pCR) to neoadjuvant therapy is strongly associated with favorable outcomes, particularly for triple-negative (TNBC) and HER2-positive subtypes [256,257]. The 5-year event-free survival (EFS) in the KEYNOTE-522 trial for early TNBC treated with pembrolizumab plus chemotherapy was 84.5% versus 76.8% with placebo (HR 0.63; 95% CI 0.48–0.82) [273].
By Stage
| Stage | Five Yr Survival | Context |
|---|---|---|
| Stage 0 (DCIS) | Not explicitly stated; the 15-year breast cancer mortality is 1.7% for BCT [29]. | Based on SEER data of 140,366 patients with DCIS [29]. |
| Stage I–II invasive (node-negative, HR-positive/HER2-negative) | 5-year distant recurrence risk <4% for 21-gene recurrence score 0–10; 9-year DFS with endocrine therapy alone 94% for RS 11–25 in TAILORx (postmenopausal) [353]. | TAILORx trial N=6711 [353]. |
| Stage III (node-positive, HR-positive/HER2-negative) | 10-year DFS 55% with CAF followed by tamoxifen for RS ≥31 vs 43% with tamoxifen alone in SWOG 8814 [350]. | Secondary analysis of SWOG 8814 [350]. |
| TNBC (stage II–III, with pembrolizumab) | 3-year EFS 84.5% vs 76.8% (HR 0.63; 95% CI 0.48–0.82) from KEYNOTE-522 [273]. | KEYNOTE-522 trial N=1174 [273]. |
Prognostic Factors
- Tumor size, axillary lymph node status, histologic grade, estrogen receptor (ER) and progesterone receptor (PR) status, HER2 expression, Ki-67 index, gene expression profiles (e.g., 21-gene recurrence score, 70-gene signature, PAM50, Breast Cancer Index), LVI, age, menopausal status, response to neoadjuvant therapy (pCR, RCB), and germline BRCA1/2 mutation status.
- The magnitude of endocrine therapy benefit is dependent on ER expression level and recurrence score [352,353].
- For DCIS, risk factors for ipsilateral breast tumor recurrence include larger DCIS size, palpable mass, grade III, margins ≤2 mm, ER-negative, and age <50 [DCIS-1].
Follow UpClick to collapse
Post Curative Treatment
For patients treated with curative intent (DCIS or early-stage invasive), follow-up includes regular history and physical examination, mammography, and management of treatment-related side effects. For DCIS: history and physical exam every 6–12 months for 5 years, then annually; first mammogram 6–12 months after RT (or after BCS if no RT) then annually [DCIS-2]. For invasive: history and physical exam 1–4 times per year for 5 years, then annually; mammogram every 12 months starting 6–12 months after RT [BINV-17]. No routine lab or imaging for metastases in asymptomatic patients [BINV-17]. Educate patients on lymphedema monitoring, healthy lifestyle, and endocrine therapy adherence [BINV-17].
Surveillance Rationale
The primary goals of surveillance are early detection of in-breast recurrences (either DCIS or invasive) and second primary breast cancers, as well as management of long-term treatment effects. Approximately half of DCIS recurrences are invasive. Annual mammography is the standard; no clear benefit to shorter intervals [BINV-17]. Metastatic surveillance with routine labs or imaging has no survival benefit and is not recommended [110,429-432].
Late Effects Screening
- Bone health: Baseline and periodic bone mineral density (BMD) for patients on aromatase inhibitors or ovarian failure secondary to treatment [BINV-17].
- Cardiotoxicity: For patients who received left-sided RT, anthracyclines, or HER2-targeted therapy, monitor LVEF and cardiac risk (see NCCN Survivorship) [BINV-17].
- Lymphedema: Pretreatment arm measurements and patient education; refer for lymphedema management as needed [BINV-E, BINV-17].
- Endometrial cancer: For patients on tamoxifen, yearly gynecologic assessment and rapid evaluation of vaginal spotting; routine endometrial biopsy/ultrasound not recommended [BINV-17].
- Second primary breast cancer: Consider annual MRI for those with high lifetime risk (>20% based on family history) or diagnosed at age ≤50 or dense breasts per ACR guidelines [BINV-B].
Recurrence Patterns
Most DCIS recurrences occur in the ipsilateral breast near the original site; approximately half are invasive [DCIS-1]. For invasive breast cancer, recurrences can be locoregional (in-breast, chest wall, axillary, supraclavicular) or distant. Distant metastases are most common in bone, liver, lung, and brain. Inflammatory breast cancer has high rates of locoregional and distant recurrence. For isolated locoregional recurrence, complete surgical resection with clear margins ± RT is recommended; adjuvant chemotherapy improves OS in ER-negative disease per CALOR trial [467].
Key TrialsClick to collapse
| Acronym | Full Name | Year | N | Intervention | Comparator | Population | Primary Endpoint | Key Result | Secondary Outcomes | Practice Change | Journal |
|---|---|---|---|---|---|---|---|---|---|---|---|
| TAILORx | Trial Assigning IndividuaLized Options for Treatment (Rx) | 2018 | 6711 | Chemoendocrine therapy (chemotherapy followed by endocrine therapy) | Endocrine therapy alone | HR-positive, HER2-negative, node-negative breast cancer with 21-gene recurrence score 11–25 | Disease-free survival (DFS) | Among postmenopausal patients with RS 11–25, 9-year DFS was 94% in both arms (HR 1.06; 95% CI 0.93–1.20). In premenopausal patients with RS 16–25, chemotherapy benefit was seen (HR for distant recurrence 0.44; 95% CI 0.20–0.96) [353]. | OS similar; benefit in premenopausal patients with RS 16–25 for distant recurrence. | Established that adjuvant chemotherapy can be omitted in postmenopausal node-negative patients with RS 11–25; in premenopausal patients with RS 16–25, chemotherapy (with associated ovarian suppression) may provide benefit. | New England Journal of Medicine |
| RxPONDER | Rx for Positive Node, Endocrine Responsive Breast Cancer (SWOG S1007) | 2021 | 5083 | Chemotherapy followed by endocrine therapy | Endocrine therapy alone | HR-positive, HER2-negative, 1–3 positive nodes, RS ≤25 | Invasive disease-free survival (iDFS) | In premenopausal patients, iDFS improved with chemotherapy (HR 0.6; 95% CI 0.43–0.83). In postmenopausal patients, no benefit (HR 1.02; 95% CI 0.82–1.26) [358]. | OS not significantly different overall. | Chemotherapy can be omitted in postmenopausal women with 1–3 positive nodes and RS ≤25; premenopausal women still benefit and should receive chemotherapy. | New England Journal of Medicine |
| KEYNOTE-522 | Pembrolizumab in Early Triple-Negative Breast Cancer | 2020 (primary), 2023 (updated EFS), 2025 (5-year follow-up) | 1174 | Preoperative carboplatin + paclitaxel → cyclophosphamide/doxorubicin (epirubicin) + pembrolizumab, then adjuvant pembrolizumab | Preoperative chemotherapy + placebo, then adjuvant placebo | Previously untreated stage II–III triple-negative breast cancer | Event-free survival (EFS) | 5-year EFS: 81.3% vs 72.3% (HR 0.63; 95% CI 0.49–0.81). pCR: 64.8% vs 51.2% [273,274]. | pCR, OS (not yet mature). | Established pembrolizumab plus chemotherapy as standard neoadjuvant/adjuvant therapy for high-risk TNBC. | New England Journal of Medicine (2020), Annals of Oncology (2023), JAMA (2025?) |
| OlympiA | Adjuvant Olaparib in Germline BRCA–Mutated Early High-Risk Breast Cancer | 2021 | 1836 | Adjuvant olaparib for 1 year | Placebo | gBRCA1/2 mutation, high-risk HER2-negative early breast cancer (≥pT2 or ≥pN1, residual disease after neoadjuvant or adjuvant chemotherapy) | Invasive disease-free survival (iDFS) | 4-year iDFS 82.7% vs 75.4% (HR 0.58; 95% CI 0.41–0.82). 4-year OS 89.8% vs 86.4% (HR 0.68; 95% CI 0.47–0.97) [373]. | Distant DFS, OS improved. | Adjuvant olaparib is standard for high-risk gBRCA-mutated HER2-negative breast cancer after completion of (neo)adjuvant chemotherapy. | New England Journal of Medicine |
| DESTINY-Breast04 (DB-04) | Trastuzumab Deruxtecan vs Treatment of Physician's Choice in HER2-Low Advanced Breast Cancer | 2022 | 557 | Fam-trastuzumab deruxtecan-nxki (T-DXd) | Physician's choice chemotherapy (capecitabine, eribulin, gemcitabine, paclitaxel, nab-paclitaxel) | HER2-low (IHC 1+ or 2+/ISH negative) metastatic breast cancer, previously treated with 1–2 chemotherapy lines (HR+ patients also received endocrine therapy) | PFS (in HR-positive cohort) and overall PFS | In HR-positive: median PFS 10.1 vs 5.4 months (HR 0.51; 95% CI 0.40–0.64); OS 23.9 vs 17.6 months (HR 0.69; 95% CI 0.55–0.87). In all patients: PFS 9.9 vs 5.1 months (HR 0.50). ILD 12% (0.8% fatal) [560]. | ORR, DOR, quality of life. | Established T-DXd as a new standard for HER2-low metastatic breast cancer, including HR-positive disease after endocrine therapy. | New England Journal of Medicine |
| CLEOPATRA | Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer | 2012 | 808 | Pertuzumab + trastuzumab + docetaxel (THP) | Placebo + trastuzumab + docetaxel | First-line HER2-positive metastatic breast cancer | PFS | Median PFS 18.5 vs 12.4 months (HR 0.62; 95% CI 0.51–0.75). OS benefit: HR 0.66; 95% CI 0.52–0.84 at 30-month follow-up [564,565]. | ORR, safety, quality of life. | Established THP as standard first-line therapy for HER2-positive metastatic breast cancer. | New England Journal of Medicine |
| APHINITY | Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer | 2017 (primary), 2022 (8.4-year update) | 4805 | Adjuvant chemotherapy + trastuzumab + pertuzumab for 1 year | Adjuvant chemotherapy + trastuzumab + placebo for 1 year | Node-positive or high-risk node-negative HER2-positive early breast cancer | Invasive disease-free survival (iDFS) | At 8.4 years: iDFS 86% vs 81% in node-positive (HR 0.72; 95% CI 0.60–0.87); no benefit in node-negative [408,409]. | OS not significant; cardiac safety acceptable. | Pertuzumab added to chemotherapy + trastuzumab is standard for node-positive HER2-positive early breast cancer. | New England Journal of Medicine, Annals of Oncology |
| KATHERINE | Trastuzumab Emtansine for Residual Invasive HER2-Positive Early Breast Cancer | 2019 | 1486 | Adjuvant ado-trastuzumab emtansine (T-DM1) for 14 cycles | Adjuvant trastuzumab for 14 cycles | HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy + HER2-targeted therapy | Invasive disease-free survival (iDFS) | 3-year iDFS 88.3% vs 77.0% (HR 0.50; 95% CI 0.39–0.64) [410]. | Distant recurrence, OS (mature data pending). | Standard of care for HER2-positive residual disease after neoadjuvant therapy. | New England Journal of Medicine |
| MONALEESA-2 | Ribociclib plus Letrozole in First-Line for HR+/HER2- Advanced Breast Cancer | 2018 | 668 | Ribociclib + letrozole | Placebo + letrozole | Postmenopausal, HR-positive/HER2-negative advanced breast cancer, no prior therapy for advanced disease | PFS | Median PFS 25.3 vs 16.0 months (HR 0.56; 95% CI 0.45–0.70). OS 63.9 vs 51.4 months (HR 0.76; 95% CI 0.63–0.93) [499,502]. | ORR, clinical benefit rate, safety. | Established ribociclib + letrozole as standard first-line therapy; ribociclib is the only CDK4/6 inhibitor with OS benefit in first line. | Journal of Clinical Oncology |
| ASCENT-03 | Sacituzumab Govitecan vs Chemotherapy in Untreated Advanced TNBC | 2025 | 558 | Sacituzumab govitecan-hziy | Physician's choice chemotherapy (paclitaxel, nab-paclitaxel, carboplatin/gemcitabine, eribulin, capecitabine) | Previously untreated locally advanced unresectable or metastatic TNBC (PD-L1 CPS <10 or not candidate for PD-1/PD-L1 inhibitor) | PFS | Median PFS 9.7 vs 6.9 months (HR 0.62; 95% CI 0.51–0.75). OS data immature; PFS2 benefit (HR 0.70; 95% CI 0.55–0.90) [600]. | ORR (48% vs 46%), DOR (12.2 vs 7.2 months). | Sacituzumab govitecan is a category 1 preferred option for first-line TNBC without PD-L1 CPS ≥10. | New England Journal of Medicine |
| EMBER-3 | Imlunestrant ± Abemaciclib in HR+/HER2- Advanced Breast Cancer | 2025 | 874 | Imlunestrant (oral SERD) ± abemaciclib, or imlunestrant alone | Standard endocrine therapy (fulvestrant or exemestane) | ER-positive/HER2-negative advanced breast cancer after progression on AI ± CDK4/6i | PFS | Imlunestrant alone improved PFS vs standard therapy only in ESR1-mutant tumors (5.5 vs 3.8 months; HR 0.62; 95% CI 0.44–0.82). Imlunestrant + abemaciclib improved PFS vs imlunestrant alone (9.4 vs 5.5 months; HR 0.57; 95% CI 0.44–0.73) [530]. | HR-QOL, safety (diarrhea, fatigue). | Imlunestrant is an option for ESR1-mutant advanced breast cancer after prior CDK4/6i; combination with abemaciclib may be most effective in ESR1-mutated, CDK4/6i-naïve patients. | New England Journal of Medicine |
Clinical PearlsClick to collapse
- Pearl 1: For patients with HR-positive/HER2-negative early breast cancer, the 21-gene recurrence score (Oncotype Dx) is the preferred assay to determine prognosis and predict chemotherapy benefit. For node-negative patients with RS ≤25, chemotherapy can be omitted in postmenopausal women; in premenopausal women with RS 16–25, a small benefit may exist and ovarian suppression effects should be considered [353,358].
- Pearl 2: For patients with node-positive (1–3 nodes) HR-positive/HER2-negative disease and RS ≤25, the RxPONDER trial showed chemotherapy benefit only in premenopausal women; postmenopausal women derived no benefit [358].
- Pearl 3: In HER2-positive early breast cancer, the addition of pertuzumab to trastuzumab plus chemotherapy significantly improves invasive DFS in node-positive patients (APHINITY, 11.3-year follow-up: HR 0.72; 95% CI 0.60–0.87) [MM].
- Pearl 4: For HER2-positive residual disease after neoadjuvant therapy, adjuvant T-DM1 (KATHERINE) significantly reduces recurrence risk (3-year iDFS 88.3% vs 77%; HR 0.50; 95% CI 0.39–0.64) [410]. Alternatively, fam-trastuzumab deruxtecan-nxki is now a category 1 option for high-risk patients (DESTINY-Breast05 criteria) [BINV-16].
- Pearl 5: For early triple-negative breast cancer (stage II–III), the KEYNOTE-522 regimen (carboplatin + paclitaxel → doxorubicin/cyclophosphamide + pembrolizumab preoperatively, then adjuvant pembrolizumab) is preferred. At 5 years, EFS rate 81.3% vs 72.3% (HR 0.63; 95% CI 0.49–0.81) [274].
- Pearl 6: Treatment de-escalation in older adults: Patients ≥70 years with HR-positive, HER2-negative, cN0, pT1 tumors can have RT omitted after BCS if endocrine therapy is planned (category 1) [BINV-2]. Patients >50 years, postmenopausal, with cT1N0, HR+/HER2-negative, grade 1–2 tumors (node-negative by axillary ultrasound) may be considered for omission of SLNB [BINV-1].
- Pearl 7: Axillary management: For patients with cT1–2, cN0, 1–2 positive SLNs undergoing BCS with WBRT, ALND can be omitted (ACOSOG Z0011). For mastectomy patients with 1–2 positive SLNs, axillary RT may replace ALND (AMAROS) [BINV-D].
- Pearl 8: For metastatic HR-positive/HER2-negative breast cancer, first-line endocrine therapy plus CDK4/6 inhibitor is preferred over chemotherapy regardless of visceral involvement, unless visceral crisis. Ribociclib has demonstrated OS benefit in MONALEESA-2 and -7 [502,503]. Fam-trastuzumab deruxtecan is now an option for HER2-low (IHC 1+ or 2+/ISH negative) patients after endocrine therapy (DESTINY-Breast06) [560].
- Pearl 9: For metastatic triple-negative breast cancer with PD-L1 CPS ≥10, first-line therapy with pembrolizumab plus chemotherapy (KEYNOTE-355) or sacituzumab govitecan + pembrolizumab (ASCENT-04) is category 1 preferred [597,599]. For PD-L1 CPS <10, sacituzumab govitecan (ASCENT-03) is preferred [600].
- Pearl 10: For patients with germline BRCA1/2 mutations and metastatic HER2-negative breast cancer, PARP inhibitors (olaparib or talazoparib) are category 1 preferred options, especially in earlier lines of therapy [643,645].
Special SituationsClick to collapse
Breast Cancer in Males (Sex Assigned at Birth)
Breast Cancer During Pregnancy
Phyllodes Tumor (Benign, Borderline, Malignant)
Paget Disease of the Breast
Inflammatory Breast Cancer (IBC)
Occult Primary Breast Cancer Presenting as Axillary Metastases
Oligometastatic Stage IV Breast Cancer
Guidelines ResourcesClick to collapse
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Breast Cancer, Version 5.2026
AJCC Cancer Staging Manual, 8th Edition – Breast Cancer
ASCO/CAP HER2 Testing Guideline (2023) and ER/PR Testing Guideline (2020)
SSO/ASTRO/ASCO Consensus Guideline on Margins for Breast-Conserving Surgery (2014 for invasive, 2016 for DCIS)
NCCN Guidelines for Breast Cancer Risk Reduction
NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate
NCCN Guidelines for Survivorship
NCCN Guidelines for Distress Management, Antiemesis, Hematopoietic Growth Factors, Palliative Care, Adult Cancer Pain, and Immune Checkpoint Inhibitor-Related Toxicities
Protective FactorsClick to collapse
- Active lifestyle and regular physical activity: Evidence suggests that an active lifestyle, healthy diet, limited alcohol intake, and achieving and maintaining an ideal body weight (BMI 20-25) may lead to optimal breast cancer outcomes [BINV-17; MS-54]. A prospective study of 1490 patients with stage I–III breast cancer showed an association between high fruit and vegetable consumption, physical activity, and improved survivorship [MS-53]. The NCCN Panel recommends an active lifestyle and ideal body weight for optimal overall health and breast cancer outcomes [MS-54].
- Tamoxifen for risk reduction: In patients with ER-positive DCIS treated with breast-conserving therapy, tamoxifen reduces risk of ipsilateral breast cancer recurrence (category 1 for those undergoing BCT followed by RT; category 2A for excision alone) [DCIS-2]. The NSABP B-24 trial showed a 3.4% absolute reduction in ipsilateral in-breast tumor recurrence risk at 13.6 years follow-up (HR 0.30; 95% CI 0.21–0.42) [MS-8]. The Breast Cancer Prevention Trial (NSABP P-1) showed a 75% reduction in occurrence of invasive breast cancer in patients with atypical ductal hyperplasia treated with tamoxifen [MS-8]. Low-dose tamoxifen (5 mg/day for 3 years) reduces intraepithelial neoplasia recurrence (HR 0.48; 95% CI 0.25–0.89) [MS-8].
- Aromatase inhibitor therapy for risk reduction: For postmenopausal patients with ER-positive DCIS treated by wide local excision ± RT, anastrozole provides comparable benefit to tamoxifen with a different toxicity profile (IBIS-II and NSABP B-35 trials) [MS-8-9]. Anastrozole resulted in a statistically significant decrease in breast cancer-free interval events compared with tamoxifen (HR 0.73; 95% CI 0.56–0.96) in the NSABP B-35 study [MS-9].
- Breastfeeding: Breastfeeding after breast-conservation therapy for breast cancer is not contraindicated, and may offer protective effects for the contralateral breast, though the guideline does not explicitly state a risk reduction effect [BINV-C]. The NCCN Panel notes that breastfeeding during active treatment with chemotherapy and endocrine therapy is not recommended [BINV-C].
- Bisphosphonate therapy for bone health and potential risk reduction: The use of bisphosphonates (oral/IV) is acceptable to maintain or improve bone mineral density and reduce risk of fractures in postmenopausal patients receiving adjuvant aromatase inhibitor therapy [BINV-K 1 of 4]. A meta-analysis by the Early Breast Cancer Trialists' Collaborative Group showed adjuvant bisphosphonates reduce bone recurrence (RR 0.83) and breast cancer mortality in postmenopausal patients [MS-45].
- Ovarian suppression with GnRH agonists for fertility preservation: Randomized trials showed that GnRH agonists administered during adjuvant chemotherapy protect against ovarian failure and reduce the risk of early menopause, and improve the probability of pregnancy from 11% to 21% in patients with HR-negative early-stage breast cancer [MS-12]. Smaller experiences in HR-positive disease show conflicting results [MS-12].